Publications

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.

Laursen KB, Mongan NP, Zhuang Y, Ng MM, Benoit YD, Gudas LJ.  2013.  Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene.. Nucleic Acids Res. 41(13):6430-43.

Benoit YD, Lepage MB, Khalfaoui T, Tremblay E, Basora N, Carrier JC, Gudas LJ, Beaulieu J-F.  2012.  Polycomb repressive complex 2 impedes intestinal cell terminal differentiation.. J Cell Sci. 125(Pt 14):3454-63.

Mongan NP, Martin KM, Gudas LJ.  2006.  The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures.. Mol Carcinog. 45(12):887-900.

Kashyap V, Laursen KB, Brenet F, Viale AJ, Scandura JM, Gudas LJ.  2013.  RARγ is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells.. J Cell Sci. 126(Pt 4):999-1008.

Amat R, Gudas LJ.  2011.  RARγ is required for correct deposition and removal of Suz12 and H2A.Z in embryonic stem cells.. J Cell Physiol. 226(2):293-8.

Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ.  2004.  Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.. Clin Cancer Res. 10(10):3429-37.

Sheren-Manoff M, Shin SJ, Su D, Bok D, Rando RR, Gudas LJ.  2006.  Reduced lecithin:retinol acyltransferase expression in human breast cancer.. Int J Oncol. 29(5):1193-9.

Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JLiao, Gudas LJ, Mongan NP.  2009.  Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs.. Stem Cells Dev. 18(7):1093-108.

Urvalek AM, Gudas LJ.  2014.  Retinoic acid and histone deacetylases regulate epigenetic changes in embryonic stem cells.. J Biol Chem. 289(28):19519-30.

Touma SEllen, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM.  2005.  Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.. Clin Cancer Res. 11(9):3558-66.

Li R, Faria TN, Boehm M, Nabel EG, Gudas LJ.  2004.  Retinoic acid causes cell growth arrest and an increase in p27 in F9 wild type but not in F9 retinoic acid receptor beta2 knockout cells.. Exp Cell Res. 294(1):290-300.

Liu L, Gudas LJ.  2002.  Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines.. J Cell Physiol. 193(2):244-52.

Thompson JR, Gudas LJ.  2002.  Retinoic acid induces parietal endoderm but not primitive endoderm and visceral endoderm differentiation in F9 teratocarcinoma stem cells with a targeted deletion of the Rex-1 (Zfp-42) gene.. Mol Cell Endocrinol. 195(1-2):119-33.

Tighe AP, Gudas LJ.  2004.  Retinoic acid inhibits leukemia inhibitory factor signaling pathways in mouse embryonic stem cells.. J Cell Physiol. 198(2):223-9.

Marino A, Sakamoto T, Tang X-H, Gudas LJ, Levi R.  2018.  A Retinoic Acid -Receptor Agonist Exerts Cardioprotective Effects.. J Pharmacol Exp Ther. 366(2):314-321.

Su D, Gudas LJ.  2008.  Retinoic acid receptor gamma activates receptor tyrosine kinase Tie1 gene transcription through transcription factor GATA4 in F9 stem cells.. Exp Hematol. 36(5):624-41.

Gillespie RF, Gudas LJ.  2007.  Retinoic acid receptor isotype specificity in F9 teratocarcinoma stem cells results from the differential recruitment of coregulators to retinoic response elements.. J Biol Chem. 282(46):33421-34.

DiKun KM, Tang X-H, Fu L, Choi ME, Lu C, Gudas LJ.  2024.  Retinoic acid receptor α activity in proximal tubules prevents kidney injury and fibrosis.. Proc Natl Acad Sci U S A. 121(7):e2311803121.

Tang X-H, Gambardella J, Jankauskas S, Wang X, Santulli G, Gudas LJ, Levi R.  2021.  A Retinoic Acid Receptor β 2 Agonist Improves Cardiac Function in a Heart Failure Model.. J Pharmacol Exp Ther. 379(2):182-190.

Melis M, Trasino SE, Tang X-H, Rappa A, Zhang T, Qin L, Gudas LJ.  2023.  Retinoic Acid Receptor β Loss in Hepatocytes Increases Steatosis and Elevates the Integrated Stress Response in Alcohol-Associated Liver Disease.. Int J Mol Sci. 24(15)

Tang X-H, Melis M, Lu C, Rappa A, Zhang T, Jessurun J, Gross SS, Gudas LJ.  2021.  A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease.. J Biol Chem. 297(6):101331.

Melis M, Tang X-H, Attarwala N, Chen Q, Prishker C, Qin L, Gross SS, Gudas LJ, Trasino SE.  2021.  A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes.. Biofactors.